Locust Walk Partners, a transaction advisory firm that supports biopharmaceutical companies, has hired Chris Ehrlich as managing director. Based in San Francisco, Ehrlich will be responsible for expanding and managing the firm’s west coast practice.
Locust Walk Partners, LLC, a transaction advisory firm that supports biopharmaceutical companies, is pleased to announce that biotech industry and venture capital veteran Chris Ehrlich has joined the firm as Managing Director. Based in San Francisco, Mr. Ehrlich will be responsible for expanding and managing the firm’s west coast practice.
Prior to Locust Walk, Mr. Ehrlich was a Managing Director at InterWest Partners, during which time he served on the boards of KAI Pharmaceuticals (acquired by Amgen) and Biomimetic Therapeutics, Inc. (acquired by Wright Medical Technologies). He currently sits on the boards of Transcept Pharmaceuticals (NASDAQ: TSPT), Carbylan BioSurgery and Xenon Pharmaceuticals. Prior to joining InterWest, Mr. Ehrlich was Director, Licensing and Business Development at Purdue Pharma. In this position, he was responsible for developing and executing a biologic oncology strategy, including in-licensing key intellectual properties, establishing and managing collaborations with biotechnology companies and participating in the commercial operations of Purdue BioPharma, a biotechnology company located in Princeton, NJ. Prior to joining Purdue, Mr. Ehrlich worked in business development at Genentech, in venture capital at The U.S. Russia Investment Fund, and in biotechnology strategy at LEK Consulting.
“I am very pleased to be joining Locust Walk Partners at this inflection point in its lifecycle,” commented Mr. Ehrlich. “The firm has built a high quality reputation for and demonstrated a track record of success in executing high value strategic transactions. It is an ideal platform from which to help companies achieve their business and corporate development objectives.”
“We are thrilled to have an individual of Chris’ caliber on the Locust Walk team and look forward to the significant value he will bring to our firm and our clients,” said Jay Mohr, Managing Director. Geoff Meyerson, Managing Director, added “Chris’ breadth of contacts and industry knowledge will be an asset to our clients.”
About Locust Walk Partners
Locust Walk Partners has an established reputation for executing high-value transactions for prominent biopharmaceutical clients. Our teams are composed of seasoned operating executives who bring insight, analytics and discipline into every deal process and strategic engagement.
We are located in the biotech hubs of Cambridge, MA and San Francisco, CA. www.locustwalkpartners.com